Current and future management of chronic spontaneous urticaria and chronic inducible urticaria

Abstract

Background: Chronic urticaria (CU), characterized by ≥6 weeks of intense pruritus, remains a debilitating condition for patients. New and safe treatments are needed to manage CU recalcitrant to standard therapy. Objective: A review of the current literature of standard and novel therapeutics in the management of CU was conducted. Methods: A literature search via a medical literature data base and clinical trial data base was conducted to identify treatment options for CU and current clinical trials. Results: Second-generation antihistamines, omalizumab, and cyclosporine remain the most proven therapeutic options for CU. Dupilumab, mepolizumab, benralizumab, tezepelumab, and CDX-0159 are all undergoing clinical trials for CU. Although ligelizumab demonstrated initial promising results, a phase III study was discontinued due to a nonsuperior clinical impact compared with omalizumab. Conclusion: Novel therapies are needed for the treatment of recalcitrant CU. With a deeper understanding of the pathophysiology of CU, promising therapeutics are in clinical trials for CU.

Chronic Urticaria in Pregnancy: Physiologic and Hormonal Background for an Immune Skin Disease

“…28 Eosinophil cumulation in skin tissue can lead to mast cell degranulation and production of urticaria. 29,30 There is no perivascular cellular infiltration in cutaneous, and all the cellular components of blood are present in the skin of CSU patients. There is limited data about the role of lymphocytes, neutrophils, and eosinophils in CU.…”

Bilastyna – nowoczesny lek przeciwhistaminowy

“…Bierze bardzo istotny udział we wczesnej fazie reakcji alergicznej, ale też uczestniczy w fazie przewlekłej przez wpływ na dendrycyty i makrofagi oraz na komórki śródbłonka i nabłonka [25]. Dlatego też leki przeciwhistaminowe II generacji będące odwrotnymi agonistami receptora H 1 (LPH) odgrywają ważną rolę w farmakoterapii alergicznego zapalenia spojówek, ANN oraz pokrzywek [26,27]. Bilastyna, należąca do grupy piperydyn, została wprowadzona na rynek w 2010 r. i jest najnowszym LPH II generacji.…”